产品信息
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述(Description)
HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell Line
应用说明(Application)
• Binding assay by FACS and cell based ELISA
生长特性(Growth Properties)
Adherent
筛选标记(Selection Marker)
Puromycin (5 μg/mL)
培养基(Complete Growth Medium)
DMEM medium + 10% FBS
冻存液(Freeze Medium)
10% DMSO + 90% FBS
装量(Quantity)
1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.
存储(Storage)
Frozen in liquid nitrogen.
支原体检测(Mycoplasma Testing)
Negative
无菌检测(Sterility Testing)
Negative
使用说明(Instructions for Use)
See data sheet for detailed culturing and assay protocol.
产品数据图
Receptor Assay

FACS assay shows that Biotinylated Human 4-1BB, Fc,Avitag (41B-H82F8) can bind to HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell Line (CHEK-ATP039). HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell was red line, Negative control HEK293 cells was grey line (QC tested).
Protocol
产品评论 发表评论

背景
4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.